Albireo to Present at the William Blair Biotech Focus Conference 2022
30 Juni 2022 - 2:00PM
Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company
developing novel bile acid modulators, today announced
participation at the William Blair Biotech Focus Conference July
12-13, 2022. Ron Cooper, President and Chief Executive Officer,
will take part in a fireside chat during the conference. Ron and
Simon Harford, Chief Financial Officer, will also host meetings
during the conference.
The fireside chat will be accessible on the Albireo website
under the Events & Presentations page at
https://ir.albireopharma.com/events-presentations, and will be
archived and available for 30 days following the event.
About Albireo
Albireo Pharma is a rare disease company focused on the
development of novel bile acid modulators to treat rare pediatric
and adult liver diseases. Albireo’s lead product, Bylvay, was
approved by the U.S. FDA as the first drug for the treatment of
pruritus in all types of progressive familial intrahepatic
cholestasis (PFIC), and it is also being developed to treat other
rare pediatric cholestatic liver diseases with Phase 3 trials in
Alagille syndrome (ALGS) and biliary atresia, as well as Open-label
Extension (OLE) studies for PFIC and ALGS. In Europe, Bylvay
has been approved for the treatment of PFIC with pricing listing
in Germany and guidance from the National Institute
for Health and Care Excellence (NICE) recommending Bylvay for
use in the National Health Service in England,
Wales and Northern Ireland. The Company has also
completed a Phase 1 clinical trial for A3907 to advance development
in adult cholestatic liver disease, with IND-enabling studies
progressing with A2342 for viral and cholestatic liver disease.
Albireo was spun out from AstraZeneca in 2008 and is headquartered
in Boston, Massachusetts, with its key operating subsidiary in
Gothenburg, Sweden. For more information on Albireo, please visit
www.albireopharma.com.
Media Contact:Colleen Alabiso,
857-356-3905, colleen.alabiso@albireopharma.com Lance
Buckley, 917-439-2241, lbuckley@lippetaylor.com
Investor Contact:Hans Vitzthum, LifeSci
Advisors, LLC., 617-430-7578
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
Von Apr 2023 bis Apr 2024